SCHEMBL29414342

SCHEMBL29414342

CNCCCCCNc1cccc2c1CN(C1CCCNC1)C2=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2B P41595 8/20 0.41
▸ HTR2C P28335 7/20 0.41
▸ HTR2A P28223 6/20 0.41
▸ PARP1 P09874 1/20 0.40
▸ HTR3E A5X5Y0 1/20 0.40
▸ HTR3B O95264 1/20 0.40
▸ HTR3A P46098 1/20 0.40
▸ TMEM97 Q5BJF2 1/20 0.40
▸ HTR3D Q70Z44 1/20 0.40
▸ HTR3C Q8WXA8 1/20 0.40
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CDK4 P11802 1/20 0.35
▸ MAP1LC3B Q9GZQ8 1/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28692317 1.00 HTR2B (0.41) HTR2BHTR2CHTR2APARP1HTR3E
SCHEMBL30069969 0.87 PARP1 (0.43) HTR2BHTR2CHTR2APARP1HTR3E
SCHEMBL30493286 0.80 STAT3 (0.44) HTR2BHTR2CHTR2APARP1HTR3E
SCHEMBL28650618 0.79 STAT3 (0.39) HTR2BHTR2CHTR2APARP1HTR3E
SCHEMBL22940891 0.77 CRBN (0.59) MAP1LC3BJAK2CRBNAXL
SCHEMBL660471 0.74 HTR2B (0.62) HTR2BHTR2CHTR2APARP1HTR3E
SCHEMBL30659847 0.74 PARP1 (0.49) HTR2BHTR2CHTR2APARP1HTR3E
SCHEMBL30376302 0.74 HTR2B (0.62) HTR2BHTR2CHTR2APARP1HTR3E
SCHEMBL30698072 0.74 HTR2B (0.62) HTR2BHTR2CHTR2APARP1HTR3E
SCHEMBL30459956 0.73 HTR2B (0.50) HTR2BHTR2CHTR2APARP1HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114174299-A Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use 百济神州有限公司 2022-03-11 — — CN disclosed
Send feedback